{"nctId":"NCT00703820","briefTitle":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","startDateStruct":{"date":"2008-08-04","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia"],"count":324,"armGroups":[{"label":"ADE","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cytarabine","Drug: Daunorubicin","Drug: Etoposide","Device: CliniMACS"]},{"label":"Clo/AraC","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cytarabine","Drug: Clofarabine","Device: CliniMACS"]}],"interventions":[{"name":"Cytarabine","otherNames":["Ara-C","Cytosar-U®"]},{"name":"Daunorubicin","otherNames":["Daunomycin","Cerubidine®"]},{"name":"Etoposide","otherNames":["VP-16","Vepesid®"]},{"name":"Clofarabine","otherNames":["Clolar^TM","Clofarex"]},{"name":"CliniMACS","otherNames":["Cell Selection System"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age less than or equal to 21 years at time of study entry.\n* No prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or less ) for hyperleukocytosis.\n* Written informed consent according to institutional guidelines\n* Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment\n* Male and female participants must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.\n\nExclusion Criteria:\n\n* Down syndrome\n* Acute Promyelocytic Leukemia (APL)\n* Juvenile Myelomonocytic Leukemia (JMML)\n* Fanconi anemia (FA)\n* Kostmann syndrome\n* Shwachman syndrome\n* Other bone marrow failure syndromes\n* Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.\n* Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of IT therapy, hydroxyurea, or low-dose cytarabine as stated above. The patient must have recovered from all acute toxicities from any previous therapy.\n* Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).\n* Pregnant or lactating patients.\n* Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.","healthyVolunteers":false,"sex":"ALL","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Day 22 Minimal Residual Disease (MRD) Measured by Flow Cytometry","description":"MRD-negative is defined as \\<0.1% blasts with leukemia-associated phenotype detected by flow cytometry. MRD-positive is defined as \\>=0.1% blasts with leukemia-associated phenotype detected by flow cytometry.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"57","spread":null}]},{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Alone.","description":"Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"54.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Event-free Survival of Standard Risk Patients Who Receive Chemotherapy Followed by Natural Killer Cell Transplantation.","description":"Kaplan-Meier estimate of the probability of being alive and free of relapse or second malignancy three years after protocol enrollment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":127,"n":133},"commonTop":["Allergic reaction/hypersensitivity (including drug fever)"]}}}